MA30807B1 - Compositions pharmaceutiques. - Google Patents

Compositions pharmaceutiques.

Info

Publication number
MA30807B1
MA30807B1 MA31809A MA31809A MA30807B1 MA 30807 B1 MA30807 B1 MA 30807B1 MA 31809 A MA31809 A MA 31809A MA 31809 A MA31809 A MA 31809A MA 30807 B1 MA30807 B1 MA 30807B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
pellets
salt
produced
pharmaceutically acceptable
Prior art date
Application number
MA31809A
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30807(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30807B1 publication Critical patent/MA30807B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE, EN PARTICULIER DES CAPSULES, COMPRENANT DES GRANULÉS CONTENANT DU NILOTINIB OU UN SEL DE CELUI-CI, AINSI QU'AU MOINS UN EXCIPIENT PHARMACEUTIQUEMENT ACCEPTABLE. CES GRANULÉS PEUVENT ÊTRE PRODUITS PAR UN PROCÉDÉ DE GRANULATION PAR VOIE HUMIDE.
MA31809A 2006-09-27 2009-04-22 Compositions pharmaceutiques. MA30807B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (fr) 2006-09-27 2006-09-27 Composition pharmaceutique comprenant de la nilotinib ou son sel

Publications (1)

Publication Number Publication Date
MA30807B1 true MA30807B1 (fr) 2009-10-01

Family

ID=37684496

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31809A MA30807B1 (fr) 2006-09-27 2009-04-22 Compositions pharmaceutiques.

Country Status (34)

Country Link
US (2) US8293756B2 (fr)
EP (4) EP1923053A1 (fr)
JP (2) JP5567340B2 (fr)
KR (2) KR20090076931A (fr)
CN (2) CN104306350A (fr)
AR (1) AR062980A1 (fr)
AU (1) AU2007301977B2 (fr)
BR (1) BRPI0719438B1 (fr)
CA (1) CA2662571C (fr)
CL (1) CL2007002766A1 (fr)
CO (1) CO6160288A2 (fr)
CY (2) CY1117021T1 (fr)
DK (2) DK3984528T3 (fr)
ES (3) ES2957912T3 (fr)
FI (2) FI2068839T4 (fr)
HR (2) HRP20151383T4 (fr)
HU (2) HUE063083T2 (fr)
IL (1) IL197496A (fr)
JO (1) JO3757B1 (fr)
LT (1) LT3984528T (fr)
MA (1) MA30807B1 (fr)
MX (1) MX2009003184A (fr)
MY (1) MY148237A (fr)
NO (2) NO347404B1 (fr)
NZ (1) NZ575317A (fr)
PE (2) PE20081379A1 (fr)
PL (2) PL2068839T5 (fr)
PT (2) PT2068839E (fr)
RU (1) RU2469707C2 (fr)
SI (2) SI3984528T1 (fr)
TN (1) TN2009000093A1 (fr)
TW (3) TW201418245A (fr)
WO (1) WO2008037716A2 (fr)
ZA (1) ZA200901511B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
US8933037B2 (en) 2009-09-28 2015-01-13 Medizinische Universitat Wien Methods involving PDGFRBETA inhibitors
JP5948246B2 (ja) 2009-10-23 2016-07-06 ノバルティス アーゲー Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2011CH01887A (fr) * 2011-06-02 2012-12-14
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
RU2014120792A (ru) 2011-10-28 2015-12-10 Новартис Аг Способ лечения стромальных опухолей желудочно-кишечного тракта
WO2013063003A1 (fr) 2011-10-28 2013-05-02 Novartis Ag Méthode de traitement des tumeurs stromales gastro-intestinales
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
SG11201401476TA (en) * 2011-11-14 2014-10-30 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014DN10801A (fr) 2012-07-11 2015-09-04 Novartis Ag
EP2988729A1 (fr) 2013-04-25 2016-03-02 Sun Pharmaceutical Industries Limited Forme posologique orale solide de produit pharmaceutique à rétention gastrique de nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
EP3189045B1 (fr) * 2014-08-11 2022-02-09 Sun Pharmaceutical Industries Limited Nouveaux sels de nilotinib et leurs polymorphes
US10045987B2 (en) * 2014-08-28 2018-08-14 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3429589B1 (fr) * 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Composition pharmaceutique du nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
EP4096791A1 (fr) 2020-01-31 2022-12-07 Nanocopoeia LLC Microparticules de nilotinib amorphe et leurs utilisations
WO2021222739A1 (fr) 2020-04-30 2021-11-04 Nanocopoeia, Llc Comprimé à désintégration orale comprenant une dispersion solide amorphe de nilotinib
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
CN115154437A (zh) * 2021-04-01 2022-10-11 齐鲁制药有限公司 一种含有盐酸尼洛替尼的药物组合物及其制备方法
MX2023015480A (es) 2021-06-19 2024-01-19 Helm Ag Composicion granulada que comprende nilotinib.
WO2023285981A1 (fr) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Composition pharmaceutique liquide stable de nilotinib
EP4122452A1 (fr) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Composition pharmaceutique comprenant du nilotinib et son procédé de fabrication
EP4260848A1 (fr) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Composition pharmaceutique pour forme posologique solide contenant du nilotinib et son procédé de préparation
EP4642435A1 (fr) 2022-12-29 2025-11-05 Renata Pharmaceuticals (Ireland) Limited Suspension pharmaceutique de nilotinib
WO2024194718A1 (fr) * 2023-03-22 2024-09-26 Unichem Laboratories Limited Composition pharmaceutique stable et son procédé de préparation
CN116854638A (zh) * 2023-06-05 2023-10-10 南华大学 一种含烷基链的氨基酸甲酯类化合物及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
PT1200090E (pt) 1999-08-03 2013-11-25 Icos Corp Formulação farmacêutica à base de um beta-carbolina e seu uso para tratar a disfunção sexual.
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions
EP1248869A2 (fr) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
CN1674877A (zh) * 2002-06-07 2005-09-28 兰贝克赛实验室有限公司 控释的多单位药物释放系统
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2379075T3 (es) * 2002-11-26 2012-04-20 Universiteit Gent Proceso y aparato para granulación húmeda continua de material en polvo
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (fr) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Enrobage intime d'ibuprofene avec des poloxameres afin d'ameliorer la dissolution aqueuse
EP1776102A1 (fr) 2004-07-28 2007-04-25 Ranbaxy Laboratories Limited Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
WO2006038552A1 (fr) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Composition contenant de fines particules et procédé de fabrication de ladite composition
WO2006066932A1 (fr) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Composition pharmaceutique stable comprenant une substance active sous la forme d’une solution solide
ATE525073T1 (de) * 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
EP1863491A1 (fr) * 2005-02-25 2007-12-12 Novartis AG Combinaison pharmaceutique d'inhibiteurs de bcr-abl et de raf
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
JP5546860B2 (ja) * 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
EP1923053A1 (fr) 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel

Also Published As

Publication number Publication date
TWI540128B (zh) 2016-07-01
BRPI0719438B1 (pt) 2022-04-19
CN104306350A (zh) 2015-01-28
HUE063083T2 (hu) 2023-12-28
SI2068839T2 (sl) 2023-01-31
AU2007301977A1 (en) 2008-04-03
TW201418245A (zh) 2014-05-16
CY1126116T1 (el) 2023-11-15
HRP20151383T1 (hr) 2016-01-15
PL2068839T3 (pl) 2016-06-30
ES2957912T3 (es) 2024-01-29
LT3984528T (lt) 2023-08-10
WO2008037716A3 (fr) 2008-07-17
CA2662571A1 (fr) 2008-04-03
EP3984528A1 (fr) 2022-04-20
EP2068839A2 (fr) 2009-06-17
CL2007002766A1 (es) 2008-08-08
SI2068839T1 (sl) 2016-02-29
US20130023549A1 (en) 2013-01-24
TWI428333B (zh) 2014-03-01
HUE028204T2 (en) 2016-12-28
KR20090076931A (ko) 2009-07-13
RU2469707C2 (ru) 2012-12-20
EP3984528B1 (fr) 2023-07-05
NO20220946A1 (no) 2009-04-24
HRP20151383T4 (hr) 2023-03-03
HK1133193A1 (en) 2010-03-19
CY1117021T1 (el) 2017-04-05
BRPI0719438A2 (pt) 2013-12-10
NO347404B1 (no) 2023-10-16
RU2009115782A (ru) 2010-11-10
US20100087463A1 (en) 2010-04-08
DK2068839T3 (da) 2016-01-11
DK3984528T3 (da) 2023-07-31
IL197496A0 (en) 2009-12-24
AU2007301977B2 (en) 2011-09-08
MX2009003184A (es) 2009-04-03
CO6160288A2 (es) 2010-05-20
TW200821298A (en) 2008-05-16
CA2662571C (fr) 2016-09-27
FI2068839T4 (fi) 2023-01-31
US8293756B2 (en) 2012-10-23
JP2010504942A (ja) 2010-02-18
ZA200901511B (en) 2010-02-24
TW201418244A (zh) 2014-05-16
WO2008037716A2 (fr) 2008-04-03
EP1923053A1 (fr) 2008-05-21
IL197496A (en) 2016-04-21
JP5567340B2 (ja) 2014-08-06
JO3757B1 (ar) 2021-01-31
ES2556625T3 (es) 2016-01-19
EP2068839B2 (fr) 2022-10-12
FI3984528T3 (fi) 2023-07-27
EP3009128A1 (fr) 2016-04-20
PT3984528T (pt) 2023-08-07
PT2068839E (pt) 2015-12-30
KR101598747B1 (ko) 2016-03-02
JP2014065715A (ja) 2014-04-17
NZ575317A (en) 2011-12-22
ES2951547T3 (es) 2023-10-23
PL2068839T5 (pl) 2023-01-30
MY148237A (en) 2013-03-29
HRP20230753T3 (hr) 2023-10-27
CN101516344A (zh) 2009-08-26
TN2009000093A1 (en) 2010-08-19
NO346639B1 (no) 2022-11-07
KR20140121903A (ko) 2014-10-16
AR062980A1 (es) 2008-12-17
PE20081379A1 (es) 2008-11-27
PE20120626A1 (es) 2012-06-07
EP3009128B1 (fr) 2023-07-05
SI3984528T1 (sl) 2023-09-29
NO20091501L (no) 2009-04-24
PL3984528T3 (pl) 2023-08-28
ES2556625T5 (es) 2023-03-02
US8501760B2 (en) 2013-08-06
EP2068839B1 (fr) 2015-09-23

Similar Documents

Publication Publication Date Title
MA30807B1 (fr) Compositions pharmaceutiques.
WO2007052289A3 (fr) Nouvelle composition de comprime dispersible
MA29816B1 (fr) Composes de benzimidazole thiophene
MA31898B1 (fr) Compositions pharmaceutiques
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
MA31684B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
MA30765B1 (fr) Derives innovants du thiophene
MA30806B1 (fr) Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
TW200722100A (en) A therapeutic agent for a β related disorders
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
WO2008017867A3 (fr) Composition orale solide antirétrovirale
IL193252A0 (en) N-hydroxyacrylamide compounds
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
WO2006060532A3 (fr) Formulations de benzoxazoles substitues
EA200900622A1 (ru) Фармацевтическая композиция, содержащая полиморфную форму 1 клопидогрела гидросульфата